The autonomic nervous system may play an important role in tissue autoregulation as the neurohumoral transmission process has been shown to constitute the final common pathway by which the effects of many physiological and pharmacological substances are mediated. The effects of the administration of a sympathomimetic amine cannot be accurately predicted in a subject. Choice of which sympathomimetic amine to use should be determined on the basis of data obtained in relevant clinical circumstances, but the dose should always be titrated against the effect in each individual. It is interesting that adrenaline, "the original autonomic drug" with its "venerable history"/6 is still a first line drug in many of the situations for which it was being prescribed in 1907. It is the drug of first choice in anaphylactic reactions and for severe allergic bronchospasm, and is widely used as a vasoconstrictor in surgery and with local anaesthetic agents. Adrenaline in "physiological" doses is a satisfactory and cheap alternative to other available drugs for use in septic shock and in emergence from cardiopulmonary bypass.
expecting "a triumphant demonstration of nothing", found himself "watching the mercury rise in the manometer with amazing rapidity to an astounding height" P This decided them to "forthwith conduct investigations with the employment of all the means at the disposal of the modern physiologist" .2 In 1895 they reported their findings in a classical paper; they had shown that a tiny amount of an extract of the adrenal medulla (which they correctly recognised as a "ductless secreting gland") caused a massive rise in blood pressure, not only by "contraction of the arterioles" but also by "increased rate and energy of the heart beat". 3 By 1898, LewandowskY' had shown that the effects of adrenaline on an organ were almost identical to stimulating the sympathetic nerves to that organ. In 1905, Elliot, after a systematic survey of this phenomenon, proposed the theory of neurohumoral transmission.
In 1907 a list of clinical indications for adrenaline that would suffice today was enumerated -as a local haemostatic (especially applied topically to mucous membranes), as a vasoconstrictor to decrease the absorption and prolong the action of local anaesthetics, as a bronchodilator in asthma, and as a circulatory stimulant in collapse associated with marked vasodilation or insufficiency of cardiac action. 2 In 1910, Barger and Dales studied a number of amines chemically related to adrenaline. They determined the structural requirements for adrenaline-like activity, and grouped the active compounds under the general heading of "sympathomimetic amines". They made the important observations that there were qualitative as well as quantitative differences between the substances, and that some of the effects of these amines could be competitively blocked by certain alkaloids of ergot and by phenoxybenzamine, whereas other effects remained unchanged in the presence of these blocking agents.
In 1921, Otto Loewi 6 provided proof of the theory of chemotransmission with his classical experiments on the isolated frog heart. He demonstrated that the perfusate of a heart undergoing nervous stimulation in an organ bath would exert predictable effects on another frog's heart. Adrenaline was generally believed to be the chemotransmitter in man until von Euler 7 in 1946 showed that the peripheral sympathetic chemotransmitter was in fact noradrenaline, the biological precursor of adrenaline.
In 1948 Ahlquist 8 proposed the existence of two different types of receptors -alphareceptors, which were blocked by the known antagonists such as phenoxybenzamine, and beta-receptors, for which no antagonist was known at that time. The sympathomimetic amines could then be classified according to their relative potencies as alpha or beta agonists. In 1958 the first beta-receptor blocker, dichloroisoprenaline, was described, and since then a number of increasingly specific alpha and beta agonists and antagonists have been developed.
Since the early 1950s the development of new techniques has allowed advances to be made on many fronts. New assay techniques for catecholamines in tissue and blood have achieved progressively greater sensitivity and speci fici ty. 9 Histochemical and cytochemical techniques have allowed mapping of adrenergic neuron systems. These techniques, combined with differential and density ultracentrifugation and advances in biochemical techniques have allowed great progress to be made in elucidating the mechanisms involved in the storage, release, metabolism and reuptake of catecholamines.
Von Euler had described the presence of noradrenaline in the central nervous system (eNS) in the late 1940s but it was not until 1954 that Vogt suggested, on the basis of new information about its distribution, that adrenaline was a neurotransmitter in the eNS. Noradrenergic and dopaminergic systems have now been mapped in the eNS and there is evidence that adrenaline may play a role as a mammalian central transmitter in several pathways originating in the medulla oblongata. There are some important consequences of this work. Levodopa was introduced for the treatment of Parkinsonism after it was demonstrated that dopamine depletion in the nigrostriatal tract was the main lesion in this disease. New knowledge about central neurotransmitters has also had major implications for psychiatry. There is evidence that affective disorders may be due to abnormalities of catecholamine neurotransmlSSlon in the central nervous system and new hypotheses concerning the mechanism of action of drugs used in the treatment of psychoses (the tricyclic antidepressants, the neuroleptic major tranquillisers, the monoamine oxidase inhibitors, lithium, and the amphetamines), are compatible with the considerable body of physiological and pharmacological knowledge about these drugs.
It had long been recognised that the autonomic nervous system played a major role in regulating many "vegetative" functions. It was known that there were large numbers of afferent fibres carried in somatic and visceral nerves, and that in addition to spinal autonomic reflexes there was extensive central integration of these signals in the medulla Anaesthesia and Intensive Care, Vol. VIII, No. 3, August, 1980 oblongata, the hypothalamus, and the cortical areas which are involved in the regulation of functions such as blood pressure, respiration, temperature, water balance, and sleep.
The original concept of the efferent side of the autonomic nervous system was that signals were transmitted from the eNS to the peripheral sympathetic nervous system, and that effector end organ activity was determined by the rate of firing of the nerve at the relevant adrenergic varicosities (Figure 1 ). A traditional image of the sympathetic nervous system had emerged as being geared mainly for a diffuse mass efferent discharge leading to the "flight or fight" response.
However, as a result of work done in the last 20 years, it is now realised that the process of neurotransmission is extremely complex and several highly organised control mechanisms have been demonstrated that regulate effector end organ activity peripherallylO,11 ( Figure 2 ). It has been suggested that the autonomic nervous system may constitute the final common pathway for local tissue autoregulation. Thus, the day-to-day role of the autonomic nervous system is probably in the fine control of local tissue conditions and most of the efferent nerve activity is part of a highly specialised pattern of efferent discharge which is then further modified by some autoregulatory mechanisms at each effector end organ.
In the light of this information, the simplistic traditional image of the effects of alpha-and beta-agonists being determined simply by their relative intrinsic potencies and their rates of receptor occupancy must be modified. There has been shown to be a large number of substances and mechanisms that may influence the effect of sympathomimetic amines at the effector end organ. Some have been shown to have physiological or pharmacological significance, but in most instances the relative importance of the various experimentally observed phenomena is hard to determine in vivo. Extrapolation of this information from animal work and in vitro experiments to the clinical situation is hazardous. Recommendations on the use of sympathomimetic amines in man should be based only on objective observations made whilst these agents are being administered in the relevant clinical circumstances.
PHYSIOLOGY AND PHARMACOLOGY There are many factors that may influence the effects of sympathomimetic amines on end organs. They may conveniently be discussed under the headings in Figure 2 . 10 -15 1. CELL BODY A single preganglionic sympathetic nerve fibre may impinge on a large number of postganglionic nerve cells in different ganglia, and each postganglionic nerve may innervate several thousand varicosities. An efferent sympathetic response is thus necessarily somewhat "diffuse" but extensive central integration of afferent impulses occurs and there are important qualitative differences in the responses to different stimuli. There are many physiological and pharmacological factors that may influence the activity of these cells. The synthesis of the enzymes involved in the peripheral elaboration of catecholamines occurs in the cell body and hormonal influences on these cells can cause great variations in this function. Pharmacological intervention is possible at this level by drugs such as the ganglion blockers.
AXON
Sympathetic nerve fibres may be divided surgically or ablated chemically in a number of conditions; temporary blockade by a local anaesthetic agent is commonplace, either as an inevitable accompaniment to the provision of sensory neural blockade or as a specific diagnostic or therapeutic measure.
ACTION POTENTIAL
On arrival at peripheral varicosities, the action potential causes release of stored noradrenaline, apparently by fusion of the storage vesicle membrane with the cell membrane. Mobilisation of the calcium ions is thought to play an important role in this process. Bretylium blocks this process in the peripheral nervous system (but does not diffuse into the central nervous system). Drugs such as guanethidine trigger release of noradrenaline from storage vesicles causing a transient sympathomimetic effect, but ultimately leading to depletion of noradrenaline stores. Amphetamine appears to cause an increase in the release of noradrenaline and dopamine; however, to what extent this is as a result of increased release from a cytoplasmic pool of dopamine or noradrenaline, or to a prevention of reuptake is not clear. Several possible physiological control mechanisms in the immediate vicinity of the cell exist" and are considered under headings 14 to 18 below.
TYROSINE TRANSPORT
Tyrosine is actively transported into the nervous system both centrally and peripherally. It is known that several aromatic amino acids will compete for transport, but there are no known implications physiologically or pharmacologically.
TYROSINE HYDROXYLASE
Tyrosine hydroxylase (identified in 1964) is necessary for the conversion of tyrosine to dihydroxyphenylalanine (DOPA). It is unique to catecholamine containing cells and is highly substrate specific. It is 100 to 1,000 times less active than the other enzymes involved in catecholamine synthesis and it is the ratelimiting enzyme in this process. It is thus the logical step for pharmacological intervention in catecholamine synthesis. There is considerable evidence that changes in tyrosine hydroxylase activity are fundamental to catecholamine synthesis regulation. Of the several classes of known tyrosine hydroxylase inhibitors, only one, a-methyl-p-tyrosine (a substrate competitive inhibitor) has been used clinically (in the treatment of phaeochromocytoma). 6. DOPA DECARBOXYLASE DOP A decarboxylase will act on all naturally occurring aromatic L-amino acids. In the sympathetic nervous system, it converts DOPA to dopamine, but is also found in the cytoplasm of many non-catecholamine containing tissues. For these reasons, pharmacological intervention at this level has not been successful. 
Dopamine-{3-oxidase (identified in 1960) is thought to be localised in the membrane of catecholamine storage vesicles and converts dopamine to noradrenaline. It will also act on a variety of substrates besides dopamine, potentially giving rise to a number of "false transmitters" (e.g. a-methyldopa is converted to a-methylnor-adrenaline). These compete with noradrenaline for uptake into storage vesicles, leading to decreased sympathetic activity on their release, as they are less potent sympathetic agonists than noradrenaline. 8. PHENYLETHANOLAMINE-N-METHYL TRANSFERASE Phenylethanolamine-N-methyl transferase is found in the cytoplasm of adrenal medullary cells, and converts noradrenaline to adrenaline. It is also found, to some extent, in mammalian heart and eNS olfactory pathways. The envelopment of the adrenal medulla by the adrenal cortex is phylogenetically a fairly recent event and in teleological terms appears to have occurred so that adrenaline could be excreted in large amounts in response to stress. Glucocorticoids induce synthesis of phenylethanolamine-N-methyl transferase, and are carried in high concentrations to the adrenal medulla via the adrenal portal system in response to stress. 9. STORAGE Noradrenaline is stored in vesicles in the form of an adenosine triphosphatecatecholamine salt in association with a specific protein. This storage process may be interfered with by the rauwolfia alkaloids (e.g. reserpine) and by guanethidine, leading to depletion of stores of catecholamines.
MONOAMINE OXIDASE (MAO)
MAO is situated both intra-and extraneuronally but the intra-neuronal component is the most important. It acts on all the endogenous catecholamines and it has been suggested that MAO may play a role in normal catecholamine synthesis regulation by controlling the amount of dopamine available for beta oxidation. The MAO-inhibitors comprise a large number of drugs which inhibit many enzymes in addition to MAO. These drugs are used in the treatment of depression, but their clinical effects may have little to do with this aspect of their function. 11. RECEPTOR ACTlVATlON-SYMPATHOMIMETIC AMINES Noradrenaline, on release from a sympathetic nerve varicosity, diffuses across the synaptic cleft and activates the receptor. The receptors may also be activated by adrenaline released from the adrenal medulla, by "false transmitters" (see 7 above) or by exogenously administered sympathomimetic amines. Receptors have been classified as alpha, beta-l or beta-2 according to their (pharmacological) responses to a series of sympathomimetic agonists which themselves are classified according to their relative potencies as alpha or beta agonists and by whether they are catecholamines or noncatecholamines. This classification is of limited value in the physiological sense, as noradrenaline, which pharmacologically is predominantly an alpha agonist, is the peripheral sympathetic neurotransmitter and acts as a pure beta agonist in, for example, the heart. The nature and situation of the receptors is obviously of prime importance in determining the in vivo responses to sympathomimetic amines (see Table 1 ).
The relative potency of a substance as an alpha or beta agonist, its likely duration of action, and whether it acts mainly directly or indirectly, may be predicted to some extent from its molecular structure. However, it is important to note that these properties will vary considerably from organ to organ, from subject to subject and from species to species.
Beta-phenylethylamine may be regarded as the parent compound of the sympathomimetic amines (see Figure 3 ). Substitutions may be made on any carbon atom or on the amino group to yield a large number of compounds.
The Catecholamines
Ortho-dihydroxybenzene is known as "catechol". This denotes a benzene ring with two hydroxyl groups on adjacent carbon atoms, compared with phenol which has only one hydroxyl group. The catechol derivatives occurring in nature have these hydroxyl groups on the 3rd and 4th carbon atoms of the benzene ring; thus the sympathomimetic amines with this configuration in the benzene ring have become known as catecholamines. The catecholamines have several important unique properties and include all the endogenously 8 classified adrenergic receptors as alpha or beta according to their responses to a range of sympathomimetic agonists. The beta receptors were subsequently subdivided into beta-I and beta-2.132 Much of this information was derived from in vitro studies and as the situation, type and sensitivity of receptors is important in determining the response to agonists, extrapolation should be made from in vitro studies to in vivo with caution.
Alpha Effects
In general, excitation of smooth muscle leading to:contraction of arterioles (especially of skin and mucous membranes) contraction of systemic veins contraction of skeletal muscle and cardiac muscle arterioles (in large doses only) contraction of gastro-intestinal and urinary sphincters contraction of the pregnant uterus contraction of the radial muscle of the eye (mydriasis) contraction of pilomotor muscles 8eta-l Effects In general, excitation of the heart leading to:increased contractility of both atria and ventricles increased automaticity of atria and ventricles and of the conducting system increased conduction velocity in the SA node, atria, A-V node, His-purkinje fibres and ventricles glycogenolysis and lipolysis 8eta-2 Effects In general, relaxation of smooth muscles, leading to:vasodilatation of coronary and skeletal muscle arterioles bronchodilatation decreased motility and tone of the gastro-intestinal tract relaxation of the detrusor muscle of the bladder relaxation of the pregnant uterus vasodilation of abdominal visceral arterioles relaxation of the ciliary muscle of the eye occurring sympathomimetic amines. They are characterised by having very short biological half-lives (of the order of 20 seconds), due to rapid reuptake mainly by sympathetic nervous tissue. 16 All are also liable to degradation by monoamineoxidase and catechol-omethyltransferase. All exert the majority of their effects by direct action on the receptors.
Substitution on the beta carbon atom is associated with a great increase in potency and thus adrenaline, noradrenaline and isoprenaline are approximately 100 times more potent than dopamine. Substitution on the amine part of the molecule is associated with increased beta agonist effect. Thus adrenaline is a more potent beta agonist than noradrenaline. Isoprenaline is virtually a pure beta agonist. Dopamine, in addition, has effects on specific dopaminergic receptors on mesenteric and renal blood vessels, causing vasodilatation. There are specific dopaminergic receptor blockers (such as the phenothiazines). 17 
Noncatecholamines
All the noncatecholamines exert their effects at least to some extent by release of noradrenaline from stores in adrenergic nerve terminals and, in part, by direct action on effector cells. However, their effects are by no means typical of those of noradrenaline, presumably because they exert characteristic direct agonist effects on their own. As with the catecholamines, substitution on the amine increases the beta agonist effect. The beta-l agonists all have substitutions on the amine group, but depend for their beta-l specificity on other substitutions in the benzene ring. None are degraded by catechol-omethyltransferase and those with substitutions on the alpha carbon as well will not be metabolised by monoaminoxidase either. Their half-lives are thus measured in hours rather than seconds. 
Alpha Agonists
In normal man doses of noradrenaline greater than 5 !1g/min, of adrenaline greater than 20 !1g/min, and of dopamine greater than 600 !1g/min usually produce alpha agonist effects. 
Amines. Noncatecholamines -" Agonists.
Metaraminol, phenylephrine and methoxamine are powerful noncatecholamine alpha agonists, with half lives of between 30 and 60 minutes. The alpha agonists usually cause increases in systolic and diastolic blood pressure, with a baroreceptor reflex mediated decrease in heart rate and cardiac output. 18 Ephedrine, phenylpropanolamine, and the imidazoline derivatives have some beta agonist effect as well and are found as traditional components of proprietary mixtures and as topical agents. These agents also have significant central stimulant effects which have not gone unnoticed by various subcultures.
Beta Agonists
Noradrenaline, adrenaline and dopamine are all beta agonists at low doses, but the beta agonist effect is over-ridden by the alpha agonist effect as the dosage increases. 19 . 2o Isoprenaline is the archetypal beta agonist. Isoprenaline thus causes an increase in heart rate and cardiac output, dilatation of skeletal muscle and coronary arterioles, and bronchodilatation. As the blood pressure falls due to its net vasodilator effect, there is an additional increase in heart rate via the baroreceptor reflex. 21 
Beta-J Agonist
Dobutamine, a new synthetic catecholamine (with the same formula as dopamine except for substitution on the amine) is a specific beta-I agonist; as it has less beta-2 effect on vessels there is less reflex increase in heart rate for the same positive inotropic effect. 21-23.23a Beta-2 Agonists Beta-2 agonists relax bronchi and the pregnant uterus. They have much less cardiac stimulant effect than isoprenaline or dobutamine. Tremor is common as a side effect and anxiety and weakness may also occur.
RECEPTOR RESPONSE
The effect of activating a receptor will depend on its site, situation, and sensitivity (Table I) .
There is evidence that the receptors can increase several thousand fold in sensitivity in the absence of normal amounts of agonist. This provides an explanation for the long-known phenomenon of "denervation hypersensitivity" and constitutes another peripheral feedback mechanism for the maintenance of homeostasis. There is some evidence that the enzyme adenyl cyclase is the beta receptor. On activation by a beta agonist more adenosine triphosphate is converted to cyclic-3-5adenosine monophosphate (the "second messenger"), which activates the appropriate enzyme system in that cell for the response to take place. Little is known about the alpha receptor mechanism.
Specific blockers for alpha, beta-I, and beta-2 receptors are the subject of another review in this issue. 13 . CA TECHOL-O-METHYL TRANSFERASE (COMT) COMT is found in the cytoplasm of most animal tissues, particularly in kidney, liver, CNS and effector organs with rich sympathetic innervation. It is fairly nonspecific and catalyses the transfer of a methyl group from S-adenosyl methionine to the 3-0H of various catechol derivatives. COMT may be inhibited by pyrogallol and various tropolone derivatives. This does not increase the intensity of sympathetic stimulation, but leads to a prolongation of the response (implying that COMT may play some role in the normal termination of action of a sympathetic response). Much of the degradation of noradrenaline by COMT that does occur, occurs in the effector end organ after NA reuptake; circulating catecholamines are also rapidly degraded by COMT in the liver. z4 
UPTAKE
The shortness of the sojourn of noradrenaline in the synaptic cleft is due to the fact that rapid reuptake takes place. The termination of action of intravenously administered catecholamines is also due largely to rapid uptake into tissue and there is considerable evidence that the majority is taken up actively into sympathetic nerves by a saturable membrane transport process, with a significant amount also being taken up into the effector end organ. Drugs such as cocaine, tricyclic anti-depressants and chlorpromazine inhibit uptake both in the central nervous system and in the peripheral nervous system thus potentiating sympathetic nervous system responses. 15 . NORADRENALINE RELEASE-AUTOREGULATION BY PRESYNAPTIC RECEPTORS The regulation of noradrenaline release by noradrenaline itself (or possibly by some other substance released from the storage vesicle in association with noradrenaline) is called autoregulation. So-called alpha and beta presynaptic autoreceptors have been described; stimulation of alpha receptors inhibits noradrenaline release and stimulation of beta receptors enhances its release. It is possible that much of the low dose beta agonist effect of catecholamines in vivo may be by stimulation of these presynaptic beta autoreceptors, causing increased noradrenaline release peripherally. The range of specific presynaptic alpha and beta agonists and antagonists discovered experimentally may have pharmacological significance, but as yet these agents have not been widely used in man.
TRANS-SYNAPTIC REGULATION
Substances such as prostaglandin E z , formed after the activation of post synaptic receptors by the effector end organ, can feed back to cause inhibition of noradrenaline release. Although this is not considered to be a universal regulatory mechanism, it is thought to be of importance at certain noradrenergic neuroeffector junctions.
MUSCARINIC AND NICOTINIC RECEPTORS
There is evidence that there is adrenergic neuronal control by acetylcholine released from parasympathetic nerve terminals close to adrenergic varicosities via both muscarinic and nicotinic receptors (respectively inhibitory and facilitatory to adrenergic transmission). This mechanism has possible pharmacological implications and may play a physiological role in certain areas (e.g., the heart). Evidence for this phenomenon prompted the original Burn-Rand hypothesis that acetylcholine may normally play an intermediary role in noradrenergic neurotransmission.
AUTACOID AND HORMONAL RECEPTORS
There is also evidence that a bewildering range of locally formed or blood-borne substances may inhibit or facilitate noradrenergic neurotransmission. Angiotensin and 5-hydroxytryptamine may act as facilitators and it is suggested that angiotensin in particular may be important physiologically and in some pathophysiological states. Histamine, adenosine and enkephalin can inhibit neurotransmission although their Anaesthesia and Intensive Care, Vol. VIII, No. 3, AURust. 1980 physiological roles and pathophysiological or pharmacological importance has yet to be established.
Most structures in the body have a rich autonomic innervation. It is felt that the noradrenergic neurotransmission process may constitute a final common pathway for a host of local tissue autoregulatory mechanisms with physiological control systems acting at several stages, each of which may also be modified by pharmacological intervention or by a disease process. The effect of the administration of a sympathomimetic amine will therefore be determined not only by its intrinsic properties, but also by these peripheral mechanisms and by the pre-existing level of regional sympathetic neural activity, and will vary considerably from organ to organ in an individual under different circumstances.
There are also groups of dopaminergic, noradrenergic and adrenergic neurons in the central nervous system, each with specialised physiological functions and autoregulatory mechanisms. Pharmacological intervention is also possible at all stages in central neurotransmission and it is likely that this will lead to significant advances in the management of certain neurological and psychiatric disorders.
PHARMACODYNAMICS
Despite the enormous advances that have been made in neurophysiology and neuropharmacology in the last 80 years, the use of the sympathomimetic amines in man has remained largely empirical. It is tantalising that so little should be known about the effects of these agents in some of the clinical contexts in which they are used when there is such a huge mass of experimental information available and when the biochemical and biophysical events have been dissected in such detail. There are several fundamental reasons why this is so.
In the first place, the actions of exogenously administered sympathomimetic amines are superimposed on levels of endogenous sympathetic nervous system activity that are extremely difficult to quantitate. It is obvious from the above analysis of the possible mechanisms by which autonomic nervous system activity may be physiologically or pharmacologically modulated, that any prediction as to the general or regional level of activity of the sympathetic nervous system in an individual is highly suspect without some direct measurement.
The significance of measurements of both endogenous and exogenous catecholamine levels in plasma is considered below.
Secondly, the measurement of both endogenous and exogenous catecholamine levels in plasma, and of the effects of catecholamines in vivo, has been fraught with difficulties, even in experimental animals. There is enormous variability between subjects, and even within a subject effects may change at different rates in different regions.
Thirdly, there are several homeostatic mechanisms which tend, following administration of a sympathomimetic amine, to return the physiological situation to its previous status. For instance, reflex bradycardia and a decrease in cardiac output are the immediate consequences of a pressor effect due to injection of a sympathomimetic amine, and actual demonstration of a direct beta agonist effect on the heart is only possible after gross pharmacological or surgical intervention.
A fourth problem is that of physiological reactance. For example, a knowledge of the effects of exogenously administered sympathomimetic amines on the control of regional circulation and the distribution of blood is of vital importance in the clinical contexts in which these substances are used. However, most of the available experimental methods themselves cause gross disurbances to regional circulatory control mechanisms. Anaesthesia, for example, or the effects on vessel walls of the placement of flow probes both cause significant disturbances to regional circulation.
These problems are compounded by ethical considerations in normal man. Finally, the generalisations that appear to be true in normal man have in many instances been shown not to be so in certain disease states in which catecholamines are used. An argument will be presented, when making any therapeutic decisions, for only considering data obtained in man in relevant clinical circumstances.
ENDOGENOUS CA TECHOLAMINES AT REST
Much effort has been expended on measuring plasma catecholamine levels since the first attempt by Batelli in 1902; however, it is only in the last decade that resting physiological levels have been able to be measured with some degree of reliability.9 Endogenous noradrenaline in blood represents spillover from sympathetic synaptic clefts; approximately 30070 of this circulating noradrenaline is removed on each passage through the lungs,25 and for this reason venous noradrenaline levels are higher than arterial levels. The adrenal medulla is the source of endogenous adrenaline in the blood and because uptake occurs in the tissues, arterial levels are higher than venous levels. 16 ,25 Several workers have emphasised that no conclusions should be drawn from individual measurements in man as plasma catecholamines simply represent the balance between release and uptake in a particular portion of the circulation, They are also subject to considerable variations; for example, the apprehension associated with venesection can cause significant changes in plasma catecholamine levels. 26 In addition, a circadian rhythm has been reported for blood catecholamines with levels falling in the early hours of the morning. 27 ,28 Noradrenaline levels have been shown to increase progressively with increasing age. 29 Venous plasma of resting recumbent humans contains about 0.05 '1g/ml of adrenaline, about the same amount of dopamine and about 0.3 '1g/ml of noradrenaline. 26 ,2832 The half lives of endogenous catecholamines in plasma are only of the order of 20 seconds. 16
ENDOGENOUS CATECHOLAMINES IN STRESS AND DISEASE
Plasma catecholamine levels have been measured in association with a wide variety of stressful circumstances and disease states. Exercise will increase plasma noradrenaline levels up to sixfold but adrenaline levels only start to rise with severe exercise. 24 ,26,33-35 Patients with myocardial infarction have elevated noradrenaline and adrenaline levels (up to 4 I')g/ml of noradrenaline and 0.27 I')g/ml of adrenaline) and the level corresponds with the clinical severity of the disease. 26 ,36,37 Plasma adrenaline has been shown to increase 30 fold (to 1.8 '1g/ml) in man in response to insulin and to fall sharply to normal levels on administration of sugar. 26, 38 With well managed anaesthesia and postoperative pain control there may be virtually no increase in plasma catecholamine levels, but levels may be markedly increased (up to 4 I')g/ml) with hypotension or inadequate pain control. 3944 Tan et al. 39 have shown that noradrenaline levels up to 3.5 '1g/ml in hypotensive patients represent a response within the homeostatic range because as soon as blood pressure is restored to normal there is a sharp fall in the levels of circulating catecholamines. Adrenaline levels in septic shock have been recorded at 3 I')g/ml and noradrenaline levels at up to 7 y/g/mI. 45 A depletion of adrenal medullary stores of adrenaline was demonstrated in this study in patients who had died from septic shock.
There is much discussion as to whether resting catecholamine levels are elevated in essential hypertension; it would seem that abnormal catecholamine synthesis or release may play a role in some hypertensives. 46 -5o Resting catecholamine levels of between 5 and 10 '1g/ml are commonplace in patients with phaeochromocytomas 26 ,51 and of around 20 I')g/ml in Raynaud's disease. In both diseases, the circulating plasma catecholamine levels have been measured at up to 98 '1g/ml which is approximately 500 times the normal resting level. 26 No correlation has been shown between plasma noradrenaline levels, representing spillover from every sympathetically innervated organ in the body, and physiological parameters such as heart rate or blood pressure. 24 ,26,28 Endogenous plasma catecholamine levels are thus nonspecific indicators of the level of sympathetic nervous system activity, and are subject to much variability between subjects; they do not correlate with physiological parameters as they do not represent the concentration in the region of the receptors of any particular effector end organ.
EXOGENOUS CATECHOLAMINES-PLASMA LEVELS
Plasma levels of adrenaline and noradrenaline have been measured during constant rate infusions, and there have been a number of consistent findings. 24, [52] [53] [54] [55] 38 The half life of exogenously administered catecholamines is between one and two minutes and thus a steady state level is achieved between five and ten minutes after the beginning of a constant rate infusion. There is significant clearance of both noradrenaline and adrenaline by the liver 26 and of noradrenaline by the lungs 25 as well as by peripheral tissue uptake mechanisms; uptake does not appear to occur as rapidly with exogenous as with endogenous catecholamines. Fairly predictable plasma levels are achieved, and increases in plasma levels as a result of increases in infusion rates within individuals are linear up to infusion rates of 40 f-lg/min of adrenaline and noradrenaline. This implies that endogenous catecholamines do not make a significant contribution to the measured plasma levels under these circumstances. There are no significant changes in endogenous levels of a catecholamine that is not being infused. Plasma noradrenaline levels increase by between 1 and 211g/ml for each 0.01 f-lg/kg/min infused and plasma adrenaline levels increase by between 0.5 and 1 I1g/ml for each 0.01 f-lg/kg/min infused. It has been proposed that adrenaline is cleared more rapidly because it increases liver blood flow and therefore the rate of its own degradation by COMT.26
EXOGENOUS CATECHOLAMINES -EFFECTS IN NORMAL MAN
"The specific circulatory responses to the administration of an autonomic drug are infinitely variable in any single experimental animal or human subject or patient. " 56 The effects of the catecholamines on blood pressure, heart rate, and cardiac output, have been described under heading 11 above.
It is important to note that all the catecholamines exert predominantly beta effects in low doses and alpha effects at high doses. ' 9 ,20 Considerable variability between individuals is the rule. For example Manger et al. ,50 on infusing noradrenaline at increasing rates, found that the blood pressure fell consistently in some subjects.
Infusion of adrenaline at 7 f-lg per minute leads to a great increase in hepatic blood flow, oxygen utilisation and glucose mobilisation. Noradrenaline infusion leads to a small decrease in hepatic blood flow with one-sixth of the glucose mobilisation. 57 Dopamine leads to an increase in hepatic blood flow mediated both by beta and dopaminergic receptors. 17 Anaesthesia and Intensive Care, Vol. VIll, No. 3, August, 1980 When noradrenaline or adrenaline are infused into normal subjects until pressor effects are obtained, adrenaline causes an increase in cerebral blood flow and oxygen consumption, and noradrenaline causes a decrease in cerebral blood flow with unchanged oxygen consumption. 58 Infusion of noradrenaline or adrenaline at a rate which produces a pressor effect, also leads to a decrease in renal plasma flow and sodium excretion, an unchanged glomerular filtration rate, and generally an increase in urine flow (although the effect on urine flow was variable between individuals). 59, 60 In these studies, quite large doses of catecholamines were infused. In contrast, infusion of dopamine up to 500 micrograms per minute leads to a significant increase in renal plasma flow, urine flow, and sodium excretion. 17 ,61 The glomerular filtration rate is unaffected; at higher infusion rates the alpha effect predominates, leading to decreased renal plasma flow. It has been shown that the renal vasodilator effect is mediated by specific dopaminergic receptors.
As with endogenous catecholamines, there is no correlation between plasma levels and effect. In some subjects, infusions had to be terminated because of unpleasant subjective effects or hypertension with noradrenaline and adrenaline infusions of only 10 f-lg per minute, whereas in others there was no significant effect at infusion rates of up to 50 f-lg per minute.
SYMPATHOMIMETIC AMINES IN DISEASE STATES
Catecholamines are used in the treatment of certain conditions in which there appear to be abnormalities of aspects of neurohumoral transmission. Insight into possible pathophysiological processes operating in these conditions is desirable for the rational choice of a suitable sympathomimetic amine. ASTHMA 62, 63 Asthma is a disease characterised by variable airway obstruction caused by contraction of bronchial smooth muscle and aggravated by smooth muscle and mucous gland hypertrophy and mucosal oedema.
The following account is a working hypothesis. An increase in the level of intracellular cyclic adenosine monophosphate (cAMP) causes decreased tone of the smooth muscle cells and also decreases the effectiveness of mediators (such as histamine or prostaglandins) released as a result of an antigen-antibody reaction. In asthmatics, cAMP levels are decreased and there also appears to be a relative insensitivity of beta adrenergic receptors in bronchial smooth muscle.
The aim in treatment of the disease is to increase intracellular cAMP levels. This may be achieved by intense local receptor activation by high levels of beta agonist, or by decreasing breakdown of cAMP. The xanthine derivatives inhibit phosphodiesterase, the enzyme responsible for this process.
The use of a specific beta-2 agonist allows high doses to be used without unacceptable cardiovascular sequelae. High concentrations may be achieved locally by inhalation of the agent in aerosol form. A prolonged effect is obtained as all the specific beta-2 agonists are non-catecholamines. Alpha agonists should be avoided in asthma because although they vasoconstrict the oedematous mucous membranes, they have been implicated in the genesis of asthma induced by exercise and infection.
SHOCK
Shock is a clinical syndrome in which tissue perfusion is inadequate for oxygen requirements. There has been much disagreement in the literature regarding the roles of endogenous and exogenous catecholamines in shock. It has been proposed by some workers that many of the undesirable features of shock are caused by inappropriate prolonged excessive activity of the sympathetic nervous system; the demonstration of elevated plasma catecholamine levels in shock is cited as evidence in support of this hypothesis, and alpha blockers have been advocated as part of the treatment. 6468 On the other hand, others have claimed that the infusion of various sympathomimetic amines is effective treatment of the myocardial failure that may be a precipitating or perpetuating factor in many shock states. [69] [70] [71] [72] [73] Plasma catecholamine levels in shock have been shown to be elevated both in experimental animals,64.7 4 -77 and in man. 37 .4 5 ,68 However, the levels to which they are elevated would, in normal man, by no means necessarily cause a decrease in peripheral blood flow or glomerular filtration rate. 18 ,60,59 Elevated plasma catecholamine levels in the presence of hypotension are a manifestation of a normal homeostatic response by the autonomic nervous system; the levels to which catecholamines are elevated under these circumstances have been shown to be within the homeostatic range. l9 The failing heart depends on an increased sympathetic drive to maintain an adequate cardiac output. 78, 79 It has also been shown that myocardial depression occurs early in septic shock and becomes progressively worse with time (although the cardiac output may initially be normal or increased). 70, 71, [80] [81] [82] [83] [84] [85] [86] In these circumstances, the heart is also under the considerable sympathetic drive that has been shown to be necessary for its continued function. 86 ,87,88 As the shock state progresses, the myocardium becomes less responsive to circulating catecholamines. 89, 90 Infusion of adrenaline or noradrenaline at rates of less than lO I1g per minute, which produce plasma levels that are within the range endogenously produced in shock and several other conditions,24,52,26 are sufficient to lead to clinical improvement in a significant number of shocked patients. 69 ,71,91 It is interesting to note that both in experimental animals and in man, noradrenaline content of the heart of subjects dying from myocardial failure may be less than lOOJo of normal,78,n and that the adrenal glands of patients dying from septic shock have been shown to have a much lower catecholamine content than norma1. 45 Impaired activity of tyrosine hydroxylase, the rate-limiting enzyme in noradrenaline synthesis, has been shown to play a role in the depletion of myocardial noradrenaline stores in congestive cardiac failure. 74 ,78,79 It has also been shown in a small series (five patients with severe septic shock) that although the noradrenaline levels were elevated up to 7 or 8 Ylg per ml, adrenaline levels were undetectable in human plasma before the administration of exogenous adrenaline. The restoration of plasma adrenaline levels by an intravenous infusion to those found in early septic shock, was associated with a dramatic clinical improvement. lll It would seem, therefore, that noradrenaline synthesis or release may be inadequate in the Anaesthesia and Intensive Care, Vol. VII!, No. 3, August, 1980 failing heart and that adrenaline production by the adrenal medulla may also fail in severe shock states. The considerable beta agonist drive that has been shown to be necessary for continued myocardial function under these circumstances may be provided by the infusion of exogenous catecholamines at rates designed to produce plasma levels at which beta agonist effects will predominate.
Endorphans have recently been implicated in the pathophysiology of shock, as the use of opiate antagonists has been shown to be associated with an increased blood pressure and increased survival rates in experimentally induced hypovolaemic shock. 93 It is of considerable interest to note that enkephalin is one of the substances that has been shown to act on presynaptic receptors to inhibit noradrenergic neurotransmission .11 THERAPEUTIC USES Much of the information on the therapeutic uses of sympathomimetic amines includes data obtained from observations in animal experiments or in normal man. 94 ,95 For example, most of the available information about noradrenaline and adrenaline in man is based on data obtained when these agents were infused until pressor effects were obtained, i.e., until the alpha effect predominated,50,58,59 whereas the agents are used clinically in their beta agonist dose range.
Recommendations about which sympathomimetic amine to choose should be made on the basis of data obtained in the relevant clinical circumstances. Where systemic effects are expected, the dose should always be gradually increased according to individual patient response; when the desired response is not obtained, a different agent should be tried. Pulse and blood pressure should always be monitored in these instances, as a hypertensive crisis or severe dysrhythmias may occur. In fact, these problems may occur in response to sudden noxious stimuli without any reinforcement by exogenous sympathomimetic amines. 96 Particular care should be taken in the elderly, in the critically ill, and in patients with a past history of cerebrovascular accident or myocardial infarction. A history should always be taken from patients to avoid possible drug interactions. Sympathomimetic amines are commonly found as constituents of proprietary Anaesthesia and Intensive Care, Vol. VIII, No. 3, August, 1980 remedies for coughs and colds, hay fever, asthma, and appetite suppression. Many patients in the community are on long-term treatment with antihypertensive agents, antidepressants, or the major tranquillisers. Roberts 96 has discussed the consequences of using sympathomimetic amines in patients on a beta blocker.
USE IN ASTHMA 62 ,63
The aim of treatment is to maintain patients as close to normal as possible between attacks and to treat attacks vigorously in the early stages. Isoprenaline and orciprenaline both cause more tachycardia for the same degree of bronchodilatation (particularly at high doses) than the specific beta-2 agonists salbutamol, terbutaline and fenoterol. The latter three drugs all have similar effects clinically (although fenoterol is twice as potent and has a slightly longer duration of action). The beta-2 agonists are all noncatecholamines and thus their effects last four to eight hours. Controlled dose response studies have shown conclusively that if the drugs are inhaled, there is less increase in heart rate and less tremor for the same degree of bronchodilatation than if given by the oral or intravenous route, although more than 750/0 of inhaled drug has been shown to be eventually swallowed.
The maintenance dose of salbutamol is 0.1-0.4 mg six hourly by aerosol inhalations. This may be increased to 10 mg four hourly in a severe attack; under these circumstances, administration via a nebuliser is more efficient. If the patient is unwilling or unable to inhale the drug, 100-300 /Ag may be given slowly intravenously, followed by an infusion of up to 50 /Ag per minute. In a severe acute attack, sympathomimetic amines should be used in concert with supportive measures such as oxygen therapy and reassurance, corticosteroids, and xanthine derivatives. Mechanical ventilation is very rarely necessary and is a last resort in the exhausted patient, whose bronchospasm has proven refractory to treatment.
There is some unresolved controversy about sudden deaths in association with the use of aerosols; dysrhythmias, bronchospasm due to alpha agonist effect, toxicity of the freon vehicles, and hypoxia, have all been implicated. Beta agonists do abolish the pulmonary arteriolar hypoxic vasoconstrictor reponse, and this has been shown to decrease arterial P0 2 by about 10 mm Hg on air. The freons appear to have been absolved. The aetiology is probably multi-factorial and due in part to the use of excessive doses; the incidence of death has fallen markedly in the 1970s with better patient education.
USE IN ANAPHYLAXIS 97 ,98 Adrenaline is the drug of choice in anaphylactic reactions of all types. It helps prevent histamine release as well as reducing the catastrophic bronchospasm, circulatory collapse, and oedema of mucous membranes.
Traditionally, 0.2-0.5 mg are injected subcutaneously. However, in competent hands a slow intravenous infusion of adrenaline of up to 50 /-lg per minute will provide more immediate effects and better control 99 although this may be dangerous in circumstances where ventricular tachycardia or fibrillation cannot be promptly treated. 100 Thus, one milligram of adrenaline may be diluted in 20 ml of water in syringe and injected at 1 ml per minute (or faster for the first minute) whilst feeling the pulse. A strong slowing pulse will indicate an excessive pressor response. Less than 20 /-lg per minute will usually produce a powerful beta agonist effect.
USE IN SHOCK
Shock may be caused by a decrease in the circulating blood volume, an increase in the capacity of the circulation, or by failure of the heart as a pump. In clinical shock states it is not unusual for all three mechanisms to contribute to varying extents. Sympathomimetic amines should only be considered for use in shock when treatment of the cause is under way, when full supportive measures have been instituted, and when any hypovolaemia has been corrected. Supportive measures include attention to the electrolyte, hydrogen ion, and coagulation status of the patient and, in the critically ill, endotracheal intubation and intermittent positive pressure ventilation.
Hypovolaemia is the most common primary cause of shock and may be a contributory factor in any shock state. The treatment is by infusion of an appropriate volume of a suitable fluid. In patients with a normal left ventricle, central venous pressure may be used as a guide during rapid volume replacement. However, in the elderly and in patients with coronary artery disease, chronic obstructive airways disease or hypertension, and in patients in whom there is any question of sepsis, volume loading should be undertaken whilst monitoring arterial pressure, pulmonary capillary wedge pressure, and cardiac outpUt. 101 ,I02 If facilities for measuring cardiac output and wedge pressure are not available, interstitial pulmonary oedema may be detected by chest X-ray or by the onset of dyspnoea in the non-intubated patient; alveolar oedema may be detected with a stethoscope and confirmed by chest X-ray. Measurement of the central venous pressure is not recommended in this group of patients, as it may be positively misleading. Sympathomimetic amines have no role in the treatment of pure hypovolaemic shock.
USE IN SHOCK DUE TO DECREASED VASOMOTOR TONE
Circulatory collapse due to sudden vasodilatation may occur as part of an anaphylactic reaction (see above), or as a result of an extensive regional sympathectomy due to an epidural or spinal anaesthetic. The treatment of choice is expansion of the intravascular volume by raising the legs and infusing fluid intravenously. However, in severe cases, the use of an alpha agonist may be resorted to. Metaraminol, phenylephrine, methoxamine and ephedrine have all been used for this purpose. Ephedrine (in 5 mg intravenous increments up to a total of 30 mg) has been recommended in obstetric patients as it has been shown experimentally in the pregnant ewe not to decrease uterine blood flow. 103
USE IN SEPTIC SHOCK
It has been shown experimentally and in man that vascular pooling in arterioles and venules occurs early on in septic shock,81,102,104,105 and therefore attention is directed initially towards restoration of optimal filling pressures for myocardial function. Volume loading should ideally be undertaken in small increments with frequent measurement of wedge pressure, cardiac output and arterial pressure because in addition to the left ventricular dysfunction that has been discussed above, there appear to be permeability changes in the respiratory membrane and pulmonary oedema may occur at quite low pressures in the pulmonary vasculature. 7l ,73,95 A number of patients in septic shock will respond to a volume load, and require no further therapeutic measures. At this stage, if tissue perfusion is still clinically poor, the patient is still hypotensive and oliguric, and the acidosis has not improved, then infusion of a catecholamine should be considered.
Dopamine has been recommended on theoretical grounds as the drug of first choice in septic shock because of its effects on renal vasculature and because it has proven a satisfactory agent in clinical practice. 7l ,106 However, in septic shock, both noradrenaline and adrenaline have been shown to produce an increase in urine output in the same number or more oliguric patients as dopamine,69,7I,133 and changing from noradrenaline to dopamine has been shown to cause no change in glomerular filtration rate. 106 Noradrenaline and adrenaline produce a slightly higher mean arterial pressure and less increase in heart rate for the same increase in cardiac output as dopamine. It would seem that an increase in cardiac output and mean arterial pressure without an increase in heart rate are the prime requisites in septic shock, and that direct effects on renal vasculature are not as important as in normal subjects or patients with congestive cardiac failure or myocardial infarction. In these studies it was also shown that isoprenaline caused more tachycardia and less increase in urine flow than noradrenaline or dopamine.
Adrenaline, as the drug of first choice in septic shock, has been shown to be a satisfactory agent. In a series of 66 patients with septic shock, no patient refractory to adrenaline responded to another catecholamine l33 . Thompson!06 has shown that 180,10 of patients refractory to noradrenaline or isoprenaline will respond to dopamine.
In a patient who does not respond to a volume load, an infusion of adrenaline (or noradrenaline) at 3 JAg per minute, or dopamine at 100 JAg per minute, may be instituted. A desirable response to treatment is an increase in cardiac output by 30 to 50%, an increase in mean blood pressure to a level deemed adequate for renal perfusion in that patient, a progressive improvement in tissue perfusion (manifested clinically and by a decrease in acidosis), and a marked increase in urine flow Anaesthesia and Intensive Care. Va!. Vlll, No. 3, August, 1980 in oliguric patients. No change or a slight increase (less than lO%) in heart rate is usually seen with these agents. 71 If the patient does not respond, the dose may be increased half-hourly or hourly. It is important that haemodynamic measurements and blood gases be taken before each dose increment. Adrenaline or noradrenaline in doses above 20 JAg per minute, and dopamine in doses above 700 JAg per minute, tend to have predominantly alpha agonist effects. Between one-third and one-half of oliguric patients refractory to volume loading have been reported to respond to this treatment. 7l , 106 In a recent study,l33 77% of patients responded to adrenaline infusion.
In summary, it seems that adrenaline, noradrenaline and dopamine are satisfactory agents to use in septic shock. It is essential to establish and maintain an adequate left ventricular filling pressure and to base the choice and dose of catecholamine on individual patient response, rather than on any alleged intrinsic properties of the agents used.
USE IN MYOCARDIAL INFARCTION
The fundamental problem in shock due to myocardial infarction is muscle loss and ventricular dyskinesia (once dysrhythmias have been treated), rather than an abnormality of the neurohemoral transmission process. Careful adjustment of preload and afterload (by monitoring central venous, pulmonary capillary wedge and arterial pressures) without causing increases in heart rate (and therefore myocardial oxygen consumption) may provide some increased efficiency of the heart. 107-109 Theoretically, a low dose catecholamine infusion may confer some advantages in cardiogenic shock. 108 A low dose adrenaline infusion in experimentally induced myocardial infarction in dogs has been shown to be associated with increased survival. 110 Dopamine, dobutamine, and isoprenaline have been used in man after acute myocardial infarction. Isoprenaline has been shown to increase cardiac output only by an increase in rate and not stroke volume, and to cause a marked increase in lactate production. 111 Dopamine and do but amine have been shown to cause short-term haemodynamic improvements, but no increased medium or long-term survival has been shown. 22, [112] [113] [114] 
USE IN COMPLETE HEART BLOCK
Adrenaline or isoprenaline may be infused in order to increase ventricular rate in complete heart block. This is only a temporary measure until electrical pacing is established. Adrenaline should be used if hypotension is a problem. USE IN CARDIAC ARREST 500 to 1,000 j.lg adrenaline may be injected, preferably through a central vein, to coarsen ventricular fibrillation for defibrillation. In the first few minutes after a cardiac arrest, adrenaline, isoprenaline or dopamine may be infused to establish adequate myocardial function.
USE IN RECOVERY FROM CARDIOPULMONARY BYPASS
Catecholamines are frequently used for myocardial support during emergence from cardiopulmonary bypass. Adrenaline in doses of 2 to 20 j.lg per minute,115,116 dopamine in doses up to 700 j.lg per minute,117-119 and dobutamine in doses up to 700 j.lg per minute 23 ,12o have all been shown to be satisfactory agents for this purpose. Holloway et al. 118 in comparing dopamine with isoprenaline, and Tinker et al. 21 comparing dobutamine with isoprenaline, both concluded that isoprenaline is not a drug of first choice as it causes more tachycardia and dysrhythmias for the same increase in cardiac output. Gattiker and Schmid l16 found that the greatest increase in cardiac output for the least chronotropic effect and increase in afterload, was obtained by a mixture of adrenaline (4 j.lg per minute) and dopamine (250 j.lg per minute) rather than larger doses of either of these agents on their own. Steen et al. 119 compared dopamine and dobutamine (each at doses of 350 and 700 j.lg per minute) with adrenaline (at 3j.lg per minute) and found that all were satisfactory agents; although dobutamine caused a 10070 increase in heart rate, its use was associated with as few arrythmias as adrenaline or dopamine. They reported that their most important finding, however, was the variability in response to these drugs. This underlines the importance of closely monitoring the patient and altering the dose or catecholamine chosen if a particular agent proves unsatisfactory.
In conclusion, it seems that dopamine and adrenaline are usually the most satisfactory first line drugs for myocardial support during emergence from cardiopulmonary bypass.
USl AS V ASOCONSTRICTORS Sympathomimetic amines are applied topically to mucous membranes in the upper respiratory tract, both to stop bleeding and to decrease congestion. Noncatecholamine alpha agonists such as ephedrine, phenylephrine, methoxamine and the imidazoline derivatives, are usually used to decrease mucosal oedema in allergic conditions of the upper respiratory tract because of their prolonged duration of action; however, rebound hyperaemia is a problem when their effects wear off.
Adrenaline and cocaine pastes have been applied to the upper respiratory tract for ear, nose and throat (ENT) surgery for many years; fatalities have been reported with these agents alone or in combination for more than 50 years. 121 Cocaine is likely to remain the popular lOCal anaesthetic and vasoconstrictor for use in ENT surgery, 122 one survey reporting its use by more than 90070 of surgeons for rhinoplasties and submucous resections .123 Cocaine is frequently mixed with adrenaline. However, a trial has shown that this does not increase its efficacy. 124 If cocaine is to be used, it is recommended that it be used in a plain 5070 paraffin-based paste; careful monitoring by a prepared anaesthetist is mandatory. 121 Racemic adrenaline has been used in the treatment of croup, post-intubation laryngeal oedema and tracheitis.l25, 126 Adrenaline may be infiltrated to decrease bleeding and improve visualisation in surgical procedures; it will also decrease absorption of local anaesthetic agents, thus prolonging their action and decreasing their systemic toxicity. 127 It is recommended that no more than 0.5 mg as a one in 200,000 solution be used (i.e. 0.5 mg diluted in 100 ml) and that the pulse and blood pressure be monitored during and after the infiltration. An initial increase in cardiac output of up to 60070 associated with a low peripheral resistance has been shown to be associated with the use of adrenaline with epidural anaesthesia. Evidence of beta agonist effects lasted for 2.5 hourS.128 There is frequently subjective and objective evidence of the cardiovascular effects of adrenaline when it is used as a one in 80,000 solution for dental anaesthesia. 129
Anaeslhesia and Intensive Care, Vol. VIII, No. 3, Augusr, 1980 USE IN OPHTHALMOLOGY Ten per cent phenylephrine drops are used by ophthalmologists as a mydriatic and in the treatment of glaucoma. After reviewing 18 cases of cardiac arrest in 33 reported severe adverse reactions (included in these were severe hypertension, subarachnoid haemorrhage and ventricular arrhythmias) Fraunfelder and Scafidi 130 proposed stringent guidelines for their use, including the use of a quarter strength solution in infants and the elderly. "Mydricaine" is used occasionally under general anaesthesia to dilate the pupil. 0.3 ml contains 1 mg atropine, 5 mg cocaine, and 100 J-lg adrenaline! If this mixture must be used, the anaesthetist should be warned in advance as there are usually dramatic cardiovascular sequelae.
USE IN PRE-TERM LABOUR l3l
Pre-term labour accounts for a small percentage of total births, but for the majority of neonatal morbidity and mortality. If prevention of pre-term labour by conservative management fails, pharmacological suppression of labour may be resorted to. The beta-2 agonists are one group of drugs that are commonly used; they have not been shown to be superior to other available agents such as ethanol, the prostaglandin inhibitors, magnesium sulphate, or diazoxide. The beta-2 agonist is infused intravenously in increasing doses until uterine contractions cease or side effects supervene. Tachycardia (in both mother and foetus), hypotension and tremor limit the dose. Glycogenolysis may increase insulin requirements in diabetics. Up to 300 J-lg of salbutamol may be given slowly intravenously, followed by an infusion of up to 50 J-lg per minute.
